Physician profile
Michael D Michener
NPI 1467448662
$14,327.13
in general payments reported to CMS, 2019-2025
28 companies · $3,221 in 2025
The $3,221 reported for 2025 was more than what 85% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $288 · 2020: $207 · 2021: $1,479 · 2022: $2,271 · 2023: $3,611 · 2024: $3,250 · 2025: $3,221.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,833 · Education: $250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,832.73 |
| Education | $249.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,733.96 | 2019-2025 | |
| Janssen Biotech, INC. | $2,042.72 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
| Novartis Pharmaceuticals Corporation | $1,123.21 | 2019-2025 | |
| Genzyme Corporation | $1,092.53 | 2021-2025 | |
| Lilly USA, LLC | $967.55 | 2020-2025 | Taltz, Olumiant, Ebglyss |
| E.R. Squibb & Sons, L.L.C. | $906.11 | 2022-2025 | Sotyktu |
| Ucb, INC. | $805.74 | 2021-2025 | Bimzelx, Cimzia |
| Regeneron Healthcare Solutions, INC. | $621.86 | 2019-2025 | Dupixent, Libtayo |
| Pfizer INC. | $508.46 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $464.84 | 2019-2024 | Ilumya |
| Amgen INC. | $462.32 | 2019-2025 | Otezla, Otezla |
| Leo Pharma INC. | $350.75 | 2021-2025 | Adbry, Anzupgo |
| Incyte Corporation | $305.72 | 2022-2025 | Opzelura |
| Galderma Laboratories, L.P. | $230.03 | 2024-2025 | Nemluvio |
| Arcutis Biotherapeutics, INC. | $201.17 | 2023-2025 | Zoryve |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $104.36 | 2023-2024 | Vtama |
| Eli Lilly and Company | $99.00 | 2025 | |
| Strata Skin Sciences, INC. | $79.24 | 2021-2023 | Xtrac |
| Kyowa Kirin, INC. | $54.92 | 2023-2024 | Poteligeo |
| Organogenesis INC. | $29.90 | 2025 | Puraply Wound Matrix |
| Sanofi-Aventis U.S. LLC | $23.95 | 2021 | |
| Biofrontera INC. | $20.67 | 2021 | |
| Organon LLC | $20.10 | 2025 | Vtama |
| Krystal Biotech INC | $19.95 | 2024 | Vyjuvek |
| Mimedx Group, INC. | $16.56 | 2024 | |
| Dermira, INC. | $16.32 | 2019 | |
| Arbor Pharmaceuticals, INC. | $14.05 | 2021 | |
| Merck Sharp & Dohme LLC | $11.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Michener listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.